Biofarm
I · AI Analysis
The brief
Biofarm manufactures generic and specialty pharmaceutical products across multiple therapeutic areas including cardiovascular, digestive, respiratory, and dermatological treatments [Yahoo Finance]. The company employs 374 people and operates as a subsidiary of Polish pharmaceutical group Polpharma [Yahoo Finance].
Biofarm is a Romanian pharmaceutical manufacturer founded in 1921, producing cardiovascular, digestive, respiratory, and other specialty drugs [Yahoo Finance]. The company is currently being taken private by its Polish parent Polpharma, with shares suspended from trading and minority shareholders receiving RON 1.38 per share [Ziarul Financiar]. As of June 30, 2026, Biofarm generated RON 294.3M in trailing revenue but faced a sharp 33% year-over-year decline [Yahoo Finance].
Strong balance sheet with excellent cash generation, but revenue contracted sharply and the company is transitioning to private ownership.
Sentinellis health
Financially healthy
8.9/10
7.5+ strong · 4.5–7.5 moderate · under 4.5 weak
Profitability
Returns on capital
Growth & momentum
Balance sheet
Cash generation
Value creation
Sentinellis calculation from the published statements — not a score reported by any data source. Each category is scored on the checks that had data; missing inputs are excluded rather than counted as failures.
Market capitalisation
RON 1.3B
Revenue (TTM)
RON 294.3M
Explainers
How we read these numbers
Plain-English guides · no account needed
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
ReadPiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
ReadAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
ReadII · Recent news
What moved
2 stories · ranked by relevance
- Company2026-08-21
Polpharma retrage de la tranzacţionare acţiunile Biofarm. Acţionarii minoritari primesc 1,3790 lei pe acţ - Ziarul Financiar
Ziarul Financiar
- Company2026-08-21
Acțiunile Biofarm, suspendate de la tranzacționare. Este iminent anunțul inițierii procedurii de retragere a acționarilor, în contextul dobândirii pachetului majoritar de poloonezii de la Zakłady Farmaceutyczne Polpharma - profit.ro
profit.ro
Premium · Free with any account
Revenue collapsed 33% year-over-year through June 30, 2026, a severe contraction for a mature pharmaceutical manufacturer [Yahoo Finance]
Risks
5
Opportunities
4
Red flags
4
Leadership
10
12 more findings in the full report — free with any account.
Unlock the full Biofarm analysis
Create a free account to access the complete AI-generated report with inline citations.
- 5 risks, 4 opportunities and 4 red flags — each with its source
- 100+ financial metrics with charts and benchmarks
- Full news summaries with source links
- Executive team and compensation details
III · Related
You might also read
Same sector · Healthcare — or comparable health
Want this for your watchlist?